Eli Lilly shares fall as Q1 earnings miss estimates, guidance disappoints

Published 01/05/2025, 12:06
© Reuters

Investing.com -- Eli Lilly and Company reported first-quarter earnings that fell short of analyst expectations on Wednesday, sending shares down 3.6% in premarket trading.

The pharmaceutical giant posted adjusted earnings per share of $3.34, missing the consensus estimate of $3.46. Revenue came in at $12.73 billion, slightly above the $12.72 billion analysts were expecting and up 45% YoY.

Lilly’s key diabetes and obesity drugs Mounjaro and Zepbound drove the strong revenue growth. Mounjaro sales more than doubled to $3.84 billion, while Zepbound revenue surged to $2.31 billion from $517.4 million a year ago.

However, the company lowered its full-year 2025 earnings guidance to $20.78-$22.28 per share, below the $22.40 analysts were forecasting. Lilly maintained its revenue outlook of $58-61 billion.

"Lilly had a solid start to the year, with 45% year-over-year revenue growth driven by strong sales of Mounjaro and Zepbound," said CEO David A. Ricks. "Our pipeline continued to deliver across key therapeutic areas, with product approvals in oncology and immunology, and the exciting success of our oral incretin, orforglipron, in the first of seven late-stage studies in diabetes and obesity."

Lilly said the guidance cut reflects $1.72 per share in acquired in-process research and development charges incurred in Q1.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.